PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.

Longhua Liu,Lihong Fan,Michelle Chan,Michael J. Kraakman,Jing Yang,Yong Fan,Nicole Aaron,Qianfen Wan,Maria Alicia Carrillo-Sepulveda,Alan R. Tall,Ira Tabas,Domenico Accili,Li Qiang
DOI: https://doi.org/10.2337/db20-0217
IF: 7.7
2020-01-01
Diabetes
Abstract:Cardiovascular disease (CVD) is the leading cause ofdeath in diabetic patients; however, tight glycemic control fails to lower therisk. The thiazolidinediones (TZDs), a class of PPARgagonists, are potent insulin sensitizers with anti-atherogenic properties, buttheir clinical utilization is limited by the side effects. PPARgdeacetylation on two lysine residues (K268 and K293) induces brown remodelingof white adipose tissue and uncouples TZD’s adverse effects from insulinsensitization. Here we show that PPARg deacetylation confers anti-atherogenicproperties and retains the insulin-sensitizing effects of TZD whilecircumventing its detriments. We generated mice homozygous for deacetylation-mimeticPPARg mutations K268R/K293R (2KR) mice on anLDL-receptor knockout (Ldlr–/–) background. 2KR:Ldlr–/–mice showed reduced atherosclerotic lesions compared to Ldlr–/–mice, particularly in aortic arches. With rosiglitazone treatment, 2KR:Ldlr–/– mice demonstrated a residual anti-atherogenicresponse and significant protection against bone loss and fluid retention. Theanti-atherosclerotic effect of 2KR was attributed to the protection ofendothelium, indicated by the improved endothelium-dependent vasorelaxation andrepressed expression of pro-atherogenic factors including inducible NO synthase(iNOS), IL-6, and NADPH oxidase 2 (Nox2). Therefore, manipulating PPARgacetylation is a promising therapeutic strategy to control CVD risk in diabetestreatment.
What problem does this paper attempt to address?